Host Matt Fisher talks to Dr. Joel Diamond, Chief Medical Officer at Aranscia, about defining genetics, genomics, and molecular testing; switching treatment from body area to specific genetic makeup; the connection to precision medicine and recognizing individual variations; defining pharmacogenetic … Read More
News
InterVenn Biosciences and Aranscia Expand Commercialization Partnership for GlycoKnow™ Ovarian Cancer Diagnostic Test
Aranscia’s Technology Platform to Accelerate InterVenn’s Research and Commercialization Initiatives SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 30, 2026 /PRNewswire/ — InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, and Aranscia, … Read More
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
SOUTH SAN FRANCISCO & HOUSTON – January 7, 2026 InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership where Aranscia technical and laboratory … Read More
DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects
Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ — Oncologists and pharmacy experts are reacting to last week’s Food and Drug Administration warning that requires genetic testing … Read More
Tags: chemotherapy, DPYD, FDA, Oncology
Spartanburg Regional Healthcare System (SRHS) Deploys 2bPrecise Enterprise
Multi-year partnership affirms SRHS as a leader in precision care and genomics SPARTANBURG, S.C. and HOUSTON, June 25, 2025 /PRNewswire/ — Spartanburg Regional Healthcare System (SRHS) today announced its deployment of the 2bPrecise® enterprise platform. Under this multi-year partnership, 2bPrecise-powered applications are now … Read More
Tags: Spartanburg, SRHS
Neurogen Biomarking Announces Partnership with Aranscia
Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen’s Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and Alzheimer’s Dementia CHICAGO and HOUSTON, May 21, 2025 /PRNewswire/ — Neurogen Biomarking, the world’s first ecosystem for memory loss with … Read More
PGx Biomarker Testing: Covered Soon for All Californians
Good news for CA providers and residents! Starting July 1, 2024, Pharmacogenomic (PGx) biomarker testing will be a covered benefit for all Californians*, regardless of insurance provider. PGx testing is already a covered benefit for Medicare patients. Read the press … Read More
2bPrecise Named “Best Overall Genomics Company” in 2023 MedTech Breakthrough Awards Program
Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies [Houston, TX] – May 3, 2023 – 2bPrecise, a leading provider of transformative precision medicine solutions, today announced that it is the recipient … Read More
Tags: MedTech, MedTech Breakthrough
2bPrecise Named “Best Overall Genomics Company” in 2022 MedTech Breakthrough Awards Program
Prestigious Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies PITTSBURGH, PA, – May 5, 2022 – 2bPrecise, a leading provider of transformative precision medicine solutions, today announced that it has been selected as the winner of … Read More
2bPrecise Joins the Epic App Orchard to Bring Its Precision Medicine Insights to the Point of Care
Platform delivers genetic/genomic data directly into the EHR workflow for Epic customers Raleigh, NC – Nov. 3, 2021 – 2bPrecise™ announced its Precision Health™ platform is now available in the Epic App Orchard Gallery. The App Orchard program enables developers … Read More